Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled trial of GS-6624 in advanced liver fibrosis due to NASH
2012-002488-88Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of simtuzumab in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (3 arms), sponsored by Gilead Sciences. Started Feb 2013; status: completed.
02
Drugs
simtuzumab
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2012-002488-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002488-88.